Mastering the Risk of HLA Antibodies in Kidney Transplantation: An Algorithm Based on Pretransplant Single-Antigen Flow Bead Techniques

被引:36
作者
Lefaucheur, C. [1 ]
Antoine, C. [2 ]
Suberbielle, C. [1 ]
Glotz, D.
机构
[1] St Louis Hosp, Immunol & Histocompatibil Lab, Paris, France
[2] Agence Biomed, St Denis, France
关键词
Allocation; alllosensitization; deceased donor kidneys; waiting list; DONOR-SPECIFIC ANTIBODIES; HIGHLY SENSITIZED PATIENTS; POSITIVE CROSS-MATCH; RENAL-TRANSPLANTATION; ALLOGRAFT-REJECTION; MEDIATED REJECTION; CLINICAL-RELEVANCE; HUMORAL REJECTION; DESENSITIZATION; PLASMAPHERESIS;
D O I
10.1111/j.1600-6143.2011.03560.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
The utilization of sensitive techniques of detection of HLA antibodies to define and measure sensitization has greatly evolved in recent years. We present here an approach to minimize the risk of HLA antibodies in kidney transplantation based on the evaluation of graft accessibility of sensitized patients by calculated PRA (cPRA) and estimation of potential matched donors (PMD) using a national simulation software program. This study included all registered patients on our waiting list (WL) for deceased donor (DD) kidney transplants. All patients were screened by single-antigen flow bead (SAFB) techniques. Of the 502 registered patients, 174 (34.7%) were sensitized. Among these, 48.3% (84 pts) had a cPRA>85%. For 75.3% of sensitized patients (90 pts with cPRA <= 85% and 41 pts with cPRA>85%), the flow of PMD was considered sufficient to allow a transplant avoiding all unacceptable antigens. The 41 patients with a cPRA>85% (48.8%) had a satisfactory donor flow in the framework of the national prioritization program for highly sensitized patients. Finally, 43 sensitized patients (24.7%) were deemed eligible for a strategy of higher immunological risk through desensitization protocols or transplantation against HLA-DSAs. This approach provides a logical and systematic strategy to rationalize the access of sensitized patients to kidney transplantation minimizing the risk of HLA antibodies.
引用
收藏
页码:1592 / 1598
页数:7
相关论文
共 30 条
[1]   Addition of plasmapheresis decreases the incidence of acute antibody-medited rejection in sensitized patients with strong donor-specific antibodies [J].
Akalin, Enver ;
Dinavahi, Raiani ;
Friedlander, Rex ;
Ames, Scott ;
de Boccardo, Graciela ;
Sehgal, Vinita ;
Schroeppel, Bernd ;
Bhaskaran, Madhu ;
Lerner, Susan ;
Fotino, Marileno ;
Murphy, Barbara ;
Bromberg, Jonathan S. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (04) :1160-1167
[2]   Clinical Relevance of Pretransplant Donor-Specific HLA Antibodies Detected by Single-Antigen Flow-Beads [J].
Amico, Patrizia ;
Hoenger, Gideon ;
Mayr, Michael ;
Steiger, Juerg ;
Hopfer, Helmut ;
Schaub, Stefan .
TRANSPLANTATION, 2009, 87 (11) :1681-1688
[3]   Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk:: A pilot study [J].
Anglicheau, D. ;
Loupy, A. ;
Suberbielle, C. ;
Zuber, J. ;
Patey, N. ;
Noel, L. -H. ;
Cavalcanti, R. ;
Le Quintrec, M. ;
Audat, F. ;
Mejean, A. ;
Martinez, F. ;
Mamzer-Bruneel, M. -F. ;
Thervet, E. ;
Legendre, C. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (05) :1185-1192
[4]   Efficacy of Induction Therapy with ATG and Intravenous Immunoglobulins in Patients with Low-Level Donor-Specific HLA-Antibodies [J].
Baechler, K. ;
Amico, P. ;
Hoenger, G. ;
Bielmann, D. ;
Hopfer, H. ;
Mihatsch, M. J. ;
Steiger, J. ;
Schaub, S. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (05) :1254-1262
[5]   Calculated PRA: Initial Results Show Benefits for Sensitized Patients and a Reduction in Positive Crossmatches [J].
Cecka, J. M. ;
Kucheryavaya, A. Y. ;
Reinsmoen, N. L. ;
Leffell, M. S. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (04) :719-724
[6]   Calculated PRA (CPRA): The New Measure of Sensitization for Transplant Candidates [J].
Cecka, J. M. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (01) :26-29
[7]   The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: Short waiting time and excellent graft outcome [J].
Claas, FHJ ;
Witvliet, MD ;
Duquesnoy, RJ ;
Persijn, GG ;
Doxiadis, IIN .
TRANSPLANTATION, 2004, 78 (02) :190-193
[8]   Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk [J].
Gebel, HM ;
Bray, RA ;
Nickerson, P .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (12) :1488-1500
[9]   The spectrum of antibody-mediated renal allograft injury: Implications for treatment [J].
Gloor, J. ;
Cosio, F. ;
Lager, D. J. ;
Stegall, M. D. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (07) :1367-1373
[10]   Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation [J].
Gloor, J. M. ;
Cosio, F. G. ;
Rea, D. J. ;
Wadei, H. M. ;
Winters, J. L. ;
Moore, S. B. ;
DeGoey, S. R. ;
Lager, D. J. ;
Grande, J. P. ;
Stegall, M. D. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (08) :1841-1847